Previous 10 | Next 10 |
Not a Wall, But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer Screenings PR Newswire First-of-its-kind research from the "I Am 45" poll explores why 45-year-olds are not getting screened for deadly colorectal cancer despite national scre...
2023-08-16 09:45:00 ET It's impossible to predict the future with precise accuracy, but we can make educated guesses about general trends. For example, equity markets will likely be up from their current levels by 2030. That's a safe bet, given historical patterns. It also offers investors ...
2023-08-16 09:00:00 ET Summary Exact Sciences reported strong Q2 earnings with a 24% YoY growth in core revenue and a 31% YoY surge in screening revenue. The company raised its full-year revenue guidance, but the market reacted negatively, causing a drop in share price. Despit...
2023-08-10 11:29:07 ET Summary NFJ runs a predominantly equity portfolio with convertibles thrown in. Separate teams are assigned to manage the equity and the fixed income sleeve. Options are written on the equity portion to supplement income generation. We review this clo...
2023-08-09 14:30:00 ET If you're looking for stocks that can deliver better-than-average returns in the long run, you might want to consider these two biotechs: Exact Sciences (NASDAQ: EXAS) and Vertex Pharmaceuticals (NASDAQ: VRTX) . Both companies have innovative products ...
2023-08-03 18:07:00 ET Shares of Exact Sciences Corporation (NASDAQ: EXAS) were down 11.3% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence . The healthcare company's stock closed last week at $99.04 then fell to as low as...
2023-08-02 20:08:58 ET Benchmark has cut its rating to hold on Exact Sciences ( NASDAQ: EXAS ), citing valuation. The investment bank said that while it has increased its revenue estimates for the company in the wake of a strong Q2 earnings report and raised guidance, the stock ...
2023-08-02 16:15:30 ET Exact Sciences (NASDAQ: EXAS) , the maker of the noninvasive colon cancer diagnostic Cologuard, posted better-than-expected financial results for the second quarter of 2023 after the closing bell Tuesday. The market, for its part, wasn't impressed. Exact Scien...
2023-08-01 23:30:26 ET Image source: The Motley Fool. Exact Sciences (NASDAQ: EXAS) Q2 2023 Earnings Call Aug 01, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: Exact Sciences (EXAS) Q2 2023 Earnings Call Transcript
2023-08-01 21:20:23 ET Exact Sciences Corporation (EXAS) Q2 2023 Earnings Call Transcript August 01 2023, 05:00 PM ET Company Participants Megan Jones - Vice President of Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Jeff Elliott - Chief ...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...